Abstract
Strong evidence of the favourable cost effectiveness of pravastatin prophylaxis to prevent cardiovascular disease in Canadian men has been shown by adapting the economic model of the West of Scotland Coronary Prevention Study (WOSCOPS) to the Canadian setting.*So said Jaime Caro, one of the developers of the WOSCOPS economic model, at the Third Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Philadelphia, US; May 1998]. He believes that ‘the richness of WOSCOPS data permits reasonable adjustment’,so that the economic model from Scotland can be applied to other countries. Although the model was successfully adapted to the Canadian setting, such application is ‘not straight-forward’,and involves more than cost-adjustment, he said.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
